| Autor: |
Kevin Fiscella, Mechelle Sanders, Tameir Holder, Jennifer K. Carroll, Amneris Luque, Andrea Cassells, Brent A. Johnson, Stephen K. Williams, Jonathan N. Tobin |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal of Clinical and Translational Science, Vol 4, Pp 229-232 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2059-8661 |
| DOI: |
10.1017/cts.2020.19 |
| Popis: |
The National Institutes of Health requires data and safety monitoring boards (DSMBs) for all phase III clinical trials. The National Heart, Lung and Blood Institute requires DSMBs for all clinical trials involving more than one site and those involving cooperative agreements and contracts. These policies have resulted in the establishment of DSMBs for many implementation trials, with little consideration regarding the appropriateness of DSMBs and/or key adaptations needed by DSMBs to monitor data quality and participant safety. In this perspective, we review the unique features of implementation trials and reflect on key questions regarding the justification for DSMBs and their potential role and monitoring targets within implementation trials. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
